Select Page

Nephrology & Hypertension

Dr Daniel

Dr Schwartz is passionate about managing chronic kidney disease and supporting his patients to achieve the best clinical outcomes.

ClinIcAL Focus

Areas of clinical focus & experience


Chronic Kidney Disease

Dr Schwartz works with his patients to aggressively manage risk factors for progression of disease, with a focus on lifestyle modification & evidence-based pharmaceutical intervention.


As part of chronic kidney disease care, Dr Schwartz addresses difficult to control hypertension.

Cardio-Metabolic Optimization

Kidney disease is part of a spectrum of a cardio-metabolic disorder. Dr Schwartz addresses the entire spectrum of disease through direct management or appropriate referral.

Peritoneal Dialysis

As director of the Fraser Health home dialysis program, Dr Schwartz is a passionate supporter of independent dialysis.

Interventional Nephrology

Dr Schwartz performs procedures for patients within the kidney program.

Acute Nephrology Care

Dr Schwartz provides on-call nephrology services as part of the Fraser Health Kidney program.

New Patients

Consultations require a referral from your primary care provide or specialist

Virtual visit, or in person at #100-200 Keary Street, New Westminster, BC | Map
P (604) 516-7774
F (604) 516-7764

Kidney Care Centre

Requires a referral from Dr. Schwartz’s outpatient office

#217 – 610 Sixth St (Royal City Centre Mall), New Westminster, BC
(604) 549-6300


Royal Columbian Hemodialysis Dialysis Unit | Map
(604) 520-4582 

Peritoneal Dialysis

Abbotsford Regional Hospital Peritoneal Dialysis Unit | Map
(604) 851-4769 

Royal Columbian Peritoneal Dialysis Unit | Map
(604) 520-4503 


Dr Schwartz has a wide-range of professional interests & experience.

Dr Schwartz is a nephrologist and medical lead of the Fraser Health home dialysis program. He is also Clinical Assistant Professor of Medicine at the University of British Columbia.  His clinical interests are focused on peritoneal dialysis, interventional nephrology and late stage chronic kidney disease (CKD) management. 

He also has a keen interest in knowledge translation at the point of care and the intersection of information technology with clinical medicine. He is the creator of many online and mobile medical education offerings including QxMD, and works with great medical education partners such as Lyrn.

  • Chronic Disease Management
  • Medical Information Technology
  • Procedural MEDICINE

Offering remote & virtual consultations to allow more convenient access to kidney care.


Reducing the Cost of Pharmaceutical Drugs in Canada

Reducing the Cost of Pharmaceutical Drugs in Canada

Access to CareReducing the Cost of Pharmaceuticals in Canada Canada is well-known for its universal healthcare system, which provides all citizens and permanent residents with access to medically necessary hospital and physician services without direct charges at the...

Tips for starting an SGLT2 inhibitor

Tips for starting an SGLT2 inhibitor

SGLT2i inhibitors (eg empagliflozin, dapagliflozin, canagliflozin) have a phenomenal evidence base and have been shown to be beneficial in diabetes, heart disease (particularly heart failure) and kidney disease.
Achieving a good start is important.

7 ways the EMPA-KIDNEY trial will impact clinical care in CKD

7 ways the EMPA-KIDNEY trial will impact clinical care in CKD

EMPA-KIDNEY was a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic kidney disease (CKD). The trial was stopped early due to evidence of efficacy and was reported in November 2022 at the American Society of Nephrology ‘Kidney Week’ meeting and simultaneously published in the New England Journal of Medicine

Personalized decision support and the move from NNT to iNNT

Personalized decision support and the move from NNT to iNNT

The SPRINT trial made waves in the field of hypertension, showing evidence for reduced hard clinical endpoints (a combined outcome of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes) in those patients with a BP target of 120 mm Hg systolic.